Sotera Health(US:SHC)2022-08-04 18:15Financial Performance - Q2 2022 net revenues increased by 6% to $267 million, with a 9% increase on a constant currency basis[24] - Adjusted EBITDA for Q2 2022 increased by 1% to $136 million[24] - Adjusted EPS for Q2 2022 increased from $0.26 to $0.27[24] - YTD 2022 revenue increased 8% to $503 million compared to $464 million in 2021[34] - YTD 2022 Adjusted EBITDA increased 5% to $251 million compared to $240 million in 2021[35] - YTD 2022 Adjusted EPS increased 11% from $0.44 to $0.49[37, 39] Segment Performance - Sterigenics Q2 2022 revenue increased by 9% and segment income increased by 7%[41] - Nordion Q2 2022 revenue increased by 3%, but segment income decreased by 4%[47] - Nelson Labs Q2 2022 revenue increased by 1%, but segment income decreased by 12%[52] Investments and Capital Deployment - Capital expenditures increased by approximately 60% compared to the first half of 2021[26, 59] - Net leverage is at 3.4x with continued strong liquidity[26] Market Outlook - The company estimates a total addressable market (TAM) of approximately $33 billion[11, 18] - The company estimates a serviceable addressable market (SAM) of approximately $11 billion[18] - Full-year 2022 revenue is expected to be between $1 billion and $1022 million, representing a 7% to 10% year-over-year increase[63] - Full-year 2022 Adjusted EBITDA is expected to be between $515 million and $525 million, representing a 7% to 9% year-over-year increase[63]